^
    Back
    Association details:
    Biomarker:HER-2 G780_P781dupGSP
    Cancer:Lung Adenocarcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib

    Published date:
    07/31/2020
    Excerpt:
    Patient 5 was a 60 year-old female initially presenting with advanced lung adenocarcinoma...She received two cycles of gemcitabine plus cisplatin and eight cycles of nivolumab with a confirmed PD...The result of NGS revealed HER2 insertion mutation (p.G780_P781dupGSP) (Figures 1B,D).
    Secondary therapy:
    cisplatin + gemcitabine
    DOI:
    10.3389/fonc.2020.01162